Skip to content


    DEA Class;  Rx

    Common Brand Names; Lunesta

    • Sedative/Hypnotics

    Short-acting non-benzodiazepine hypnotic.
    Rapid onset and relatively short half-life reduces ‘hangover’ effects; does not cause early-AM awakening.
    Used for treatment of insomnia.

    Indicated for the treatment of insomnia.

    Documented hypersensitivity

    Patients who have experienced complex sleep behaviors after receiving therapy

    • Headache (13-21%)
    • Unpleasant taste (17-34% in non-elderly)
    • Abnormal dreams (elderly)
    • Accidental injury (elderly)
    • Diarrhea
    • Dizziness
    • Dry mouth
    • Dyspepsia
    • Nervousness
    • Neuralgia
    • Pain
    • Pruritus
    • Rash (in non-elderly)
    • Somnolence
    • Unpleasant taste (elderly)
    • UTI
    • Agitation
    • Alopecia
    • Angioedema
    • Asthma
    • Anorexia
    • Cystitis
    • Dysphagia
    • Fever
    • Epistaxis
    • Hypertension
    • Hostility
    • Hypercholesterolemia
    • Hypokalemia

    Take immediately before going to bed – taking earlier may cause memory loss, hallucinations, dizziness, lightheadedness

    Can impair daytime function in some patients at the higher doses (2 mg or 3 mg), even when used as prescribed; monitor for next day next-day psychomotor impairment

    Take only when able to have a full night of sleep (7-8 hr); coadministration with other sedative-hypnotics at bedtime or taking eszopiclone the middle of the night is not recommended because of risk for next-day psychomotor impairment

    May cause CNS depression and impair physical and mental abilities

    May worsen clinical depression

    Use minimum dose that will effectively treat patient; write prescription for smallest quantity consistent with good patient care

    May cause abnormal thinking & bizarre behavior

    May impair ability to drive or operate heavy machinery

    Caution in history of drug or substance abuse, respiratory diseases, hepatic impairment

    Amnesia may occur

    Failure of sleep disturbance to resolve after 7-10 days may indicate psychiatric and/or medical illness

    Abrupt discontinuation or rapid dose decreases may lead to withdrawal symptoms

    Therapy can cause drowsiness and a decreased level of consciousness; patients, particularly the elderly, are at higher risk of falls

    Available pharmacovigilance data with use in pregnant women are insufficient to identify drug-associated risk of major birth defects, miscarriage, or adverse maternal or fetal outcomes

    There are no data on prescence in either human or animal milk, effects on breastfed infant, or on milk production


    3 mg/day PO.


    2 mg/day PO.


    Safety and efficacy have not been established.


    Safety and efficacy have not been established.


    tablet: Schedule IV

    • 1mg
    • 2mg
    • 3mg